Milvexian

Clinical data
Other names	BMS-986177, JNJ-70033093
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	Investigational
Pharmacokinetic data
Elimination half-life	11.4–18.1 h[1]
Identifiers
IUPAC name (9R,13S)-13-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
CAS Number	1802425-99-5
PubChem CID	118277544
DrugBank	DB16233
ChemSpider	76803905
UNII	0W79NDQ608
KEGG	D11802
ChEMBL	ChEMBL4112929
Chemical and physical data
Formula	C28H23Cl2F2N9O2
Molar mass	626.45 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O
InChI InChI=1S/C28H23Cl2F2N9O2/c1-15-3-2-4-23(20-9-16(7-8-33-20)26-21(36-27(15)43)12-35-41(26)28(31)32)39-14-34-19(11-25(39)42)18-10-17(29)5-6-22(18)40-13-24(30)37-38-40/h5-15,23,28H,2-4H2,1H3,(H,36,43)/t15-,23+/m1/s1 Key:FSWFYCYPTDLKON-CMJOXMDJSA-N

Milvexian is a factor XIa inhibitor which acts as an anticoagulant. It is taken by mouth. As of late 2021, it was under study for the prevention of blood clots in patients undergoing surgery.^[2] In 2018–2023, Bristol-Myers Squibb studied milvexian for the prevention of stroke.^[3]